Research Article

Genetic Variants of Abo Blood Group and Coronary Artery Disease

PK Chawla¹, CK Ponde², RM Rajani², AS Desphande³, RB Sawant⁴ and TF Ashavaid¹,⁵*

¹Research Laboratories, PD Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai-400016, India
²Department of Cardiology, PD Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai-400016, India
³Department of Transfusion Medicine, PD Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai-400016, India
⁴Department of Laboratory Medicine and Transfusion Medicine, Kokilaben Dhirubhai Ambani Hospital & Medical Research Centre, Andheri, Mumbai - 400053, India
⁵Department of Laboratory Medicine. P.D. Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai-400016, India

Abstract

Background: The ABO gene encodes for the blood group antigens which are expressed on the surface of RBCs, platelets and the vascular endothelium. Several recent studies and GWASs have identified ABO as a locus for thrombosis, myocardial infarction, and multiple cardiovascular risk biomarkers.

Objectives: The objective of the study was to determine the association of genetic variants in the ABO gene with coronary artery disease (CAD).

Study design-setting-patients: A total of 500 subjects including 250 angiographically verified CAD patients’ age and gender matched with 250 angiographically verified controls were recruited for the study. Genotyping of variants A2 (deletion of C; rs918130198), B (G803C;rs8176747), O1 (deletion of G; rs8176719), O2 (G802A;rs1286157771) and A1 (wild type) alleles were performed by allele specific PCR and lipid profile, hsCRP & sICAM1 levels were estimated for all subjects.

Outcome measures: This study will help understand the influence of genetic variations in the ABO genotypes on the risk of CAD amongst Indians.

Findings & interpretation: Among the blood group alleles, O1 (Cases-32%; Controls-50%; p= 0.009) and the B allele (Cases-34%; Controls-19%; p=0.01) were significantly associated with CAD while other alleles were insignificant. The O1 allele suggested an atheroprotective role while the B variant was atherogenic. Genotypically, the BB genotype was more prone to develop CAD with a 5 fold increased risk while the O1O1 genotype was at least risk protecting the individual by 2 folds. The distributions of remaining genotypic combinations of blood groups were found similar in both the groups.

Conclusion: These findings suggest the B blood group individuals especially BB genotypes to be at higher risk for CAD while the O1 allele playing an atheroprotective role.

Introduction

Coronary Artery Disease (CAD) is the leading cause of death worldwide responsible for over 7 million deaths annually. In South Asia, deaths due to CAD have increased by 87.8% between 1990 and 2010, and is predicted to increase further by 50% by 2030 [1]. India experiences the highest number of potentially productive life years lost due to cardiovascular disease; 9.2 million years in 2000 and is expected to double to 17.9 million years by 2030 [1]. Traditional risk factors of CAD include...
smoking, hypertension, diabetes, family history of CAD and biochemical markers like lipid profile. Genetics confer to about 40–60% risk of susceptibility to CAD. Genetic studies provide new insights into the pathogenesis of CAD and Myocardial Infarction (MI) [2]. Studies on identification of novel genetic risk markers, exploration of molecular mechanisms by which mutations cause CAD may be important for better refining individuals at risk for CAD [3,4].

The clinical significance of ABO blood type extends beyond transfusion medicine and solid organ / hematopoietic transplantation. To date, numerous reports have suggested important associations between ABO blood groups and various diseases e.g., gastric cancer, periodontal diseases and cardiovascular diseases [5,6]. Studies on the associations between cardiovascular disease (CVD) and ABO blood groups have a long history [7,8]. However, there is limited consensus regarding the magnitude and significance of the ABO effects at the population level and whether it relates to all disorders equally or predominantly modulates thrombotic pathways and disorders [9]. ABO blood group antigens encoded by the ABO gene at chromosome 9 are genetically transmitted from generation to generation. There are over 190 alleles defining the variations in the gene and hence tagged as subtypes of A or B or O alleles. Of these the A1, A2, B, O1 & O2 alleles are the most important ones and are considered to be important representative markers of each A, B or O type blood group [10].

Most studies have agreed the non O blood group to be at high risk for CAD [11,12]. The A/B antigens resemble in structure to several inflammatory markers like adhesion molecules, selectins etc. These antigens thus falsely trigger inflammatory pathways by influencing the plasma levels of soluble forms of inflammatory markers and activating the immune system conferring a higher risk for CAD [9]. Several GWAS have identified the ABO locus to increase soluble levels of adhesion molecules (ICAM1, VCAM1) & selectins (E-selectin, P-selectin) and also a high risk marker for MI [13–15]. In most cases, premature CAD may be linked to inheritable risk factors, and hence inheritance of the ABO groups could play an important role in development of premature CAD.

Most studies have associated the serologically determined blood groups with CAD, however, the data on genetics of ABO blood groups is lacking. Thus, we aimed to investigate the relationship between genetically determined ABO blood groups and CAD amongst Indians.

Materials & methods

Study group

The study was a 1:1 case – control study conforming to the ethical guidelines & approved by the Institutional Review Board of the Hospital. Written informed consent was taken from a total of 500 individuals visiting the P. D. Hinduja Hospital and Medical Research Center’s catheterization laboratory enrolled in this study. These included 250 angiographically verified CAD cases (> 50 % stenosis in at least one of the 3 major coronary arteries) age and gender matched with 250 angiographically confirmed CAD controls (< 30 % stenosis) [13]. Subjects with abnormal liver or kidney function were excluded from the study. A detailed proforma with information on demographics, presence of coronary risk factors such as diabetes, hypertension, smoking etc., current medication, family history of CAD, as self-reported by patients and previous coronary intervention if any were noted from the entire study group.

Molecular methods

DNA Extraction: About 5ml of venous blood sample was collected from the subjects in EDTA tube (for DNA extraction) and plain tube (for serum). The DNA was extracted by the modified salting out procedure of Miller, et al. [16]. The DNA and serum aliquots were preserved at -80°C until analysis.

PCR and DNA Sequencing: The ABO blood group was determined genetically using the 5 major alleles – A1 (wild type), A2 (deletion of C; rs918130198), B (G803C; rs8176747), O1 (deletion of G; rs8176719) and O2 (G802A; rs1286157771) alleles by conventional PCR methods. With these 5 alleles, an individual can have any one of the 15 possible genotypes e.g a B blood group individual may be BO1, BO2 or BB genotype and so on for each blood group type. These genotypes were determined with 2 singleplex and 1 multiplex Allele specific PCRs. For each PCR assay, a master mix (50μl) was prepared consisting of PCR buffer, MgCl2, dinitucleotide triphosphate mix, specific primers, Distilled water, Taq polymerase and template DNA in specific concentrations as needed. The primer sequences and PCR conditions are described in Supplementary Table 1. The PCR products were run on a standard 3% agarose gel. The allele specific PCRs contain 2 lanes – one for wild type and the other for the variant allele. The genotyping was validated by dideoxy sequencing. Representative samples of each polymorphisms were confirmed by sequencing by outsourcing the sample.

Table 1: Demographic and clinical details of study group.

<table>
<thead>
<tr>
<th>Age(years)</th>
<th>Controls(n=250) Mean±SD or N (%)</th>
<th>Cases(n=250) Mean±SD or N (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking</td>
<td>37(14.8)</td>
<td>38(15.2)</td>
<td>0.841</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>52(20)</td>
<td>51(20)</td>
<td>0.864</td>
</tr>
<tr>
<td>Hypertension</td>
<td>120(48)</td>
<td>144(57)</td>
<td>0.203</td>
</tr>
<tr>
<td>Diabetes</td>
<td>74(29)</td>
<td>116(46)</td>
<td>0.019*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Body mass index</th>
<th>Controls(n=250) Mean±SD or N (%)</th>
<th>Cases(n=250) Mean±SD or N (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (18-22.9 kg/m²)</td>
<td>28(11.2)</td>
<td>22(8.8)</td>
<td>0.639</td>
</tr>
<tr>
<td>Overweight (23-24.9 kg/m²)</td>
<td>33(13.2)</td>
<td>23(9.2)</td>
<td>0.365</td>
</tr>
<tr>
<td>Obese (&gt;25 kg/m²)</td>
<td>117(46)</td>
<td>76(30)</td>
<td>0.019*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C/o Myocardial Infarction</th>
<th>Controls(n=250)</th>
<th>Cases(n=250)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history of CAD</td>
<td>58(23)</td>
<td>100(40)</td>
<td>0.009*</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>166±41</td>
<td>167±46.6</td>
<td>0.978</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>142±76.4</td>
<td>142.5±56.9</td>
<td>0.990</td>
</tr>
<tr>
<td>HDL-C(mg/dl)</td>
<td>39±10</td>
<td>36.8±10.6</td>
<td>0.820</td>
</tr>
<tr>
<td>LDL-C(mg/dl)</td>
<td>98.3±36</td>
<td>100.7±39</td>
<td>0.896</td>
</tr>
<tr>
<td>hsCRP(mg/dl), Median</td>
<td>0.25</td>
<td>0.3</td>
<td>0.002*</td>
</tr>
<tr>
<td>sICAM1 level(ng/ml)</td>
<td>410±142</td>
<td>472.5±134.2</td>
<td>0.0001*</td>
</tr>
</tbody>
</table>

**Biochemical assay:** Lipid profile including Total Cholesterol (TC), Triglycerides (TG) & High density lipoproteins (HDL-C) were estimated from serum samples on DXC Unicell 800 Automated Analyser (Beckman Coulter) as per lab protocols. Low density lipoproteins (LDL-C) levels were calculated using the Friedwald’s formula [17]. Inflammatory biomarkers like high sensitivity C- reactive protein (hsCRP) & soluble intercellular adhesion molecule 1 (sICAM1) levels were estimated on DXC Automated analyser (Beckman Coulter) & ELISA respectively.

**Statistical analysis:** Statistical analyses was done by MedCalc v.15.8. Normality testing was done using Shapiro–Wilk test. The normally distributed data was expressed as mean ± standard deviation while those not normally distributed were expressed as median. Qualitative data was expressed in %. Student’s t-test or Mann Whitney test was used to compare the phenotypic variables between cases and controls while difference in genotype distribution between the groups was obtained using the chi–square test. Odds ratio was calculated to assess the risk in carriers v/s non–carriers of significant variant alleles. A p-value of less than 0.05 was considered statistically significant.

**Results**

In the present study, ABO blood group alleles were studied in 250 CAD cases and 250 age and gender matched controls.

**Demographic details**

The demographic and clinical characteristics of the study group are described in Table 1.

The percentage of males and females in the study was 66.8% and 33.2% respectively. The mean age of the subjects was 53 years. Percentage of smokers and alcoholics were similar in cases and controls. Diabetes was an independent significant risk factor of CAD seen higher in cases over controls (46% v/s 29%; p = 0.019). Hypertension was higher in cases than controls but was statistically insignificant (57% v/s 48%; p = 0.203, NS). Obesity was significantly seen higher in controls over cases (p = 0.019). Out of the 250 cases, 97 patients had a past or recent myocardial event and 41 patients had a past intervention (Angioplasty or bypass surgery). Family history was statistically significant with 40% cases and 23% controls having a positive family history (p = 0.009).

Lipid profile was done for all study subjects. Among the lipid parameters, HDL-C levels were lower in cases (36.8 mg/dl) as compared to controls (39 mg/dl) however were statistically insignificant (p = 0.820). TC, TG and LDL-C were similar between both groups. Among all biochemical parameters, only hsCRP was not normally distributed and hence expressed as median. Both the inflammatory markers, hsCRP and sICAM1 levels were significantly higher in cases than controls (p = 0.002 & p = 0.0001 respectively).

**Distribution of ABO alleles & blood group**

The distribution of ABO blood groups among cases and controls is given in Figure 1. The B allele was seen higher in cases as compared to controls (34% v/s 19%; p = 0.01) while the O1 alleles was higher in controls than cases (48% v/s 32%; p = 0.02). The remaining A1, A2 and O2 allele were almost equally distributed between cases and controls. Similarly, phenotypically, the B blood group was significantly higher in cases as compared to controls (37% v/s 24%; p = 0.04) while the O blood group was higher in controls than cases (37% v/s 22%; p = 0.02). The A and AB blood groups were uniformly distributed in cases and controls.

**Prevalence of ABO genotypes**

Among the 15 possible genotypes, the A2A2 and O2O2 were not seen in the entire study group while the A2O2 genotype was seen in only 1 control. The distribution of the genotypes between cases and controls is described in Table 2. The BB genotype was seen significantly higher in cases as compared to controls (24% v/s 6%; p = 0.0002) increasing the risk of CAD by 5 folds (OR= 4.66; 95% CI: 1.9-11.3) while the O1O1 genotype was higher in controls than cases (31% v/s 19%; p = 0.05) reducing the risk of CAD by 2 folds (OR= 1.91; 95% CI: 0.99-3.6). The other genotypes were similarly distributed in cases and controls.

**Statistically significant**

**Association of B allele with risk factors for CAD:** Of the 5 alleles studied, the B allele was significantly higher in cases than controls suggesting an atherogenic role. The risk of CAD was further evaluated among the variant allele carriers and other known CAD risk factors (Figure 2A).
It was observed that in presence of B variant allele, diabetes (p=0.006), family history of CAD (p=0.025) and low HDL (p=0.033), were independently associated risk factors for CAD. The risk of development of CAD increases by 3 folds in diabetics (OR-2.7, %95 CI= 1.5-4.75) while that in presence of family history increases by 2 folds (OR-2.06, %95 CI= 1.08-3.9). Amongst the lipid profile, the risk of disease progression increases by 2 folds with low levels of HDL (OR-1.83, %95 CI= 1.1-3.2). Since age and gender are two non-modifiable risk factors for CAD, the role of B allele was studied in these patients too. Majority of patients (75%, 83 cases and 60 controls) were in the older age group (> 50 years) while remaining quarter (25%, 27 cases and 21 controls) were in the young age group (<50 years). The number of cases and controls in each group were similar and hence statistically insignificant. The frequency of males in the study group was almost double than females. The number of females carrying the variant B allele were similar in cases and controls (n=31 in each group) while carriers of the variant B allele were significant in males increasing the risk of CAD by 2 folds (47% v/s 31% ; p=0.002; OR=1.9).

### Association of O1 allele with risk factors for CAD

The risk of CAD was further evaluated among the variant O1 allele carriers and other known CAD risk factors (Figure 2B) among cases & controls. In presence of the O1 allele, only family history of CAD (p=0.0008) plays a significant role for developing the risk of CAD by 2 folds (OR-2.06, %95 CI= 1.08-3.9) while high hsCRP (p=0.008) further increased the risk by 3 folds (OR-2.83, %95 CI= 1.35-6.0). Other factors like diabetes, high TC, was seen higher in cases as compared to controls, however, statistically insignificant. In this group too, majority of patients (74%, 82 cases and 126 controls) were in the older age group (> 50 years) while remaining quarter (26%, 29 cases and 46 controls) were in the young age group (<50 years). The number of cases and controls in each age group were similar and hence statistically insignificant. About 179 males (71 cases & 107 controls) decreasing the risk of CAD by 3 folds (p=0.0001; OR= 2.6) and 105 females (40 cases & 65 controls) carried the variant O1 allele, however, insignificant.

sICAM1 levels were significantly seen higher in cases over controls in the entire study group (p= 0.0001). However, on comparing within the blood groups, the levels were insignificant. The variant allele carriers showed elevated levels of sICAM1 among the cases as compared to controls however, the difference was statistically insignificant.

### Discussion

The clinical role of ABO blood group has been widely reported in several diseases like cardiovascular events. Several GWAS have identified the ABO locus to be associated with soluble levels of inflammatory markers like adhesion molecules and selectins. In this study, we aimed to associate the role of genetic variants of ABO gene that determine the ABO blood group with CAD and its risk factors. Our study included 500 subjects who underwent coronary catherization for coronary angiography. The 250 proven CAD patients with >50% stenosis in atleast one of the major coronary arteries were age and gender matched with angiographically proven negative controls.

In our study group, diabetes (p= 0.019), family history of CAD (p=0.009), hsCRP (p=0.002) and sICAM1 levels (p=0.0001) were found to be independent risk factors for development of CAD. Diabetes is a prime risk factor for cardiovascular disease (CVD). Hyperglycaemia, a hallmark of diabetes affects the heart muscle, causing both systolic and diastolic heart failure. Insulin
deficiency or defective insulin signalling (insulin resistance) in endothelial cells decrease the bioavailability of NO, a potent vasodilator, as well as increased secretion of the vasconstrictor endothelin-1 [16]. This process leads to release of pro-inflammatory cytokines, initiation of endothelial dysfunction and hence inflammation. Inflammation is a normal response to endothelial tissue injury involves the activation of leukocytes mediated, in part, by a family of cytokines and chemokines. Diabetes has long been considered a state of chronic, low-level inflammation, and there is some evidence to suggest that this immune activation may precede insulin resistance in diabetic and pre-diabetic states and ultimately may be the factor that initially increases cardiovascular risk in these disease processes [16,17]. Recent evidence suggests crosstalk between the molecular pathways involved in both inflammation and insulin signalling, and this cross-talk may provide clues to the strong relationship between insulin-resistant states (such as the metabolic syndrome and type 2 diabetes), inflammation, and CAD [16–18]. Proinflammatory cytokines cause or exacerbate injury by a variety of mechanisms including enhanced vascular permeability, programmed cell death (apoptosis), recruitment of invasive leukocytes, and the promotion of reactive oxygen species (ROS) production and hence initiation of fatty streak and plaque formation.

In the current study, genotyping of variants of ABO gene that determine the blood type A1 allele, A2 allele (Deletion of C), B allele (G803C), O1 (Deletion of G) and O2 allele (G802A) was performed by conventional PCR methods. Of these the B allele was significantly seen higher in cases than controls while the O1 allele was significantly higher in controls than cases. The remaining A1, A2, O2 alleles were similar between CAD cases and controls and hence insignificant.

Prior to DNA analysis of the ABO gene, serological analyses have been the practical way to determine the blood groups. These tests were based on the principle of either the presence or absence of the A or B antigens on RBCs or the presence or absence of IgM anti-A or anti-B in the serum or plasma. About 70 ABO alleles are reported to the Blood group Antigen or absence of IgM anti-A or anti-B in the serum or plasma. There is scarcity of data on genotypic association of ABO blood groups with CAD. However, this may also suggest the tendency of controls to develop CAD as they age [22-24].

A limitation of the study is the small sample size, which is further reduced during subgrouping of individual blood groups. Further studies in larger Indian cohorts are needed to be carried out to validate these results and understand the clinical role of blood groups with pathways involved in CAD progression.

Conclusion

Among the ABO blood group alleles, this study has identified the B variant allele playing an athero-protective role while the O1 allele playing an athero–protective role. These variants may be present in homozygous or heterozygous forms in individual genotypes thus implicating differed severity risk on individuals. Thus, genetic screening of patients for evaluating risk of CAD will help individuals at high risk of disease progression & better preventive management.

Acknowledgements

This work was funded by National Health and Education Society (NHES) of P. D. Hinduja National Hospital and Medical Research Centre. The authors are grateful to all study subjects for their participation in the study.

Funding

This work was funded by National Health and Education Society (NHES) of P. D. Hinduja Hospital and Medical Research Centre.

References